Retinal Blood Flow and Microthrombi in Type 1 Diabetes

Completed · Phase 2

Conditions studied: Diabetes, Diabetic Retinopathy

In brief

The project aims to find mechanisms for the abnormal retinal blood flow that in diabetic patients often precedes any evidence of clinical retinopathy and may contribute to the development of retinopathy. Specifically, the projects tests the hypothesis that reduced retinal blood flow found in young patients with type 1 diabetes reflects increased resistance in the small vessels of the retina caused by the formation of small blood clots, called microthrombi; and that antiplatelet agents normalize the reduced retinal blood flow.

Key facts

Study ID

NCT00406991

Run by

Schepens Eye Research Institute

People needed

100

Starts

2003-06-01

Expected to finish

2006-03-01

Last updated by the study team

2015-10-30

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18-45 years,
• type 1 diabetes duration 1-15 years,
• absent or minimal retinopathy (EDTRS 20).
• Age- and gender-matched healthy controls

You may not qualify if…

• smoking,
• systemic diseases other than diabetes,
• retinal diseases other than diabetic retinopathy,
• pregnancy,
• bleeding disorders,
• aspirin allergy,
• use of anti-platelet agents,
• non-steroidal anti-inflammatory agents,
• angiotensin converting enzyme inhibitors,
• angiotensin receptor antagonists,
• Vitamin E in large doses.

Where it is running

• Schepens Eye Research Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.